StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.06+0.02 (+1.92%)

Close on Nov 17, 2026Market cap $106.36MP/E –Yield –

Cellectis price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Cellectis's price to book ratio was 3.4× on Nov 11, 2026, against 5.2× a year earlier. Over the last 5 years it ranged from 0.5× to 8.2×, with a median of 1.3×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.4×−1.6
2025Dec 31, 20255.0×+3.8
2024Dec 31, 20241.2×−0.6
2023Dec 29, 20231.8×+1.3
2022Dec 30, 20220.6×−0.8
2021Dec 31, 20211.3×−2.4
2020Dec 31, 20203.7×+2.0
2019Dec 31, 20191.8×−0.5
2018Dec 31, 20182.3×−1.5
2017Dec 29, 20173.8×+1.7
2016Dec 30, 20162.1×−10.3
2015Dec 31, 201512.4×–

More Cellectis figures

See a number that looks wrong?